Q3 Performance and Segmental Breakdown
Cyient DLM reported a revenue of ₹303.30 crore for Q3 FY26, falling below expectations primarily because a large order concluded in the prior year's comparable quarter. Segment contributions showed mixed performance. Aerospace and defence, medical technology, and industrials accounted for 37%, 8%, 16%, and 30% respectively. While Aerospace and Industrials saw year-on-year growth of 14.8% and 57.6%, Defence and Medical Technology declined sharply by 88.1% and 39.3%.
The margin-accretive cables segment exhibited strong growth, up 36.6% year-on-year. Conversely, contributions from PCBA and box-build segments decreased to 51.0% and 25.8% respectively. These fluctuations highlight the diverse nature of Cyient DLM's service offerings and their varying market dynamics.
Analyst's Forward Outlook and Growth Projections
Despite the Q3 revenue miss, analysts project a gradual recovery in revenues starting from Q4 FY26. This optimism is underpinned by a robust order book and a healthy book-to-bill ratio. Management is also focused on executing deferred shipments, which is expected to boost near-term performance. Fiscal year 2027 is anticipated to be materially stronger than fiscal year 2026.
Analysts forecast that Cyient DLM will deliver consistent growth over the medium term. Expected revenue, EBITDA, and PAT to grow at compound annual growth rates of 10.6%, 13.7%, and 19.1%, respectively, between fiscal years 2025 and 2028. This sustained growth trajectory is a key factor driving the positive outlook.
Margin Expansion and Valuation
Margin improvements are also a central theme in the analyst report. Margins are expected to remain in double digits and trend higher. This is attributed to scaling volumes driving operating leverage, a structurally healthier product and industry mix, and the increasing contribution from Build-to-Service (B2S) programs. These factors are expected to enhance profitability.
Valuing the stock at a Price-to-Earnings (P/E) multiple of 26 times on FY28 estimated Earnings Per Share (EPS), analysts have maintained their 'Buy' rating. The revised target price is set at ₹416, reflecting improving earnings visibility and a strengthening margin profile. This target price suggests significant upside potential from current levels.